Speakers
John Murphy
Chief Scientific Officer
Arbor Biotechnologies
Day One
Wednesday November 17, 2021
4:30 pm | Arbor Discovery’s Novel Process and Protein Engineering Approach
Roy Ziblat
Scientific Manager
Arbor Biotechnologies
Day Two
Thursday November 18, 2021
12:45 pm | Function & Discoveries of the Arbor Discovery Line Using Type V Systems
Marco Weinberg
Vice President, Research & Development
AskBio
Day One
Wednesday November 17, 2021
12:00 pm | CRISPR Delivery via the Use of Adeno Associated Viral Vectors
9:45 am | Panel Discussion: Driving CRISPR Technology to the Clinic
Luisa Loiacono
Senior Research Scientist
AstraZeneca
Day One
Wednesday November 17, 2021
9:45 am | Panel Discussion: Driving CRISPR Technology to the Clinic
Day Two
Thursday November 18, 2021
9:15 am | Evaluating the Main Safety Considerations of Base Editing
Joseph Miano
J. Harold Harrison, MD, Distinguished University Chair in Vascular Biology
Augusta University
Jacob Layer
Senior Scientist, Group Leader
eGenesisbio
Day Two
Thursday November 18, 2021
12:15 pm | Innovating Xenotransplantation with Genome Editing
Pankaj Mandal
Senior Staff Fellow, Office of Tissues & Advanced Therapies, Division of Cellular & Gene Therapies
FDA/CBER
Day One
Wednesday November 17, 2021
9:15 am | FDA’s Regulatory Approach to CRISPR Technology
Kalina Paunovska
Postdoctoral Scholars
Georgia Institute of Technology, Dahlman Lab
Day One
Wednesday November 17, 2021
2:00 pm | CRISPR Delivery via the Use of Lipid Nanoparticles Delivery
Danilo Maddalo
Senior Scientist
Genentech
Day One
Wednesday November 17, 2021
9:45 am | Panel Discussion: Driving CRISPR Technology to the Clinic
Day Two
Thursday November 18, 2021
3:45 pm | SEMMs: Somatically Engineered Mouse Models, A New Tool for Translational Preclinical Research
Danny Dever
Head of Discovery Research
GraphiteBio
Day One
Wednesday November 17, 2021
9:45 am | Panel Discussion: Driving CRISPR Technology to the Clinic
Day Two
Thursday November 18, 2021
3:15 pm | Investigate the Therapeutic Potential of CRISPR Technology in Treating Sickle Cell Disease
Ben Kleinstiver
Assistant Professor
Mass General Hospital & Harvard Medical School
Day One
Wednesday November 17, 2021
4:00 pm | Useful Engineered CRISPR-Cas Enzymes with Enhanced Properties
Sean Burns
Vice President, Disease Biology
Intellia Therapeutics
Day Two
Thursday November 18, 2021
2:45 pm | Development of Systemic CRISPR-based Therapeutics
Triparna Sen
Assistant Attending
Memorial Sloan Kettering Cancer Center
Day Two
Thursday November 18, 2021
2:15 pm | Preclinical Platform for CRISPR-Mediated Gene Editing
Gregory Cost
Senior Director of Biology
Metagenomi
Day One
Wednesday November 17, 2021
3:30 pm | Novel CRISPR-Associated Gene-Editing Systems Discovered in Metagenomic Samples Enable Efficient & Specific Genome Engineering For Cell Therapy Development
Brett Staahl
Vice President Platform, Co- Founder
Scribe Therapeutics
Day One
Wednesday November 17, 2021
11:30 am | Solving the Challenges of Editing & In Vivo Delivery
Niren Murthy
Professor, Bioengineering
University of California at Berkeley
Day One
Wednesday November 17, 2021
1:30 pm | New Delivery Vehicles for Gene Editing Enzymes
Andrew Anzalone
Head of Prime Editing Platforms
Prime Medicine
Day Two
Thursday November 18, 2021
10:15 am | Exploring the Potential of Prime Editing
Jyun-Liang “Aaron” Lin
Scientist II
Metagenomi
Day Two
Thursday November 18, 2021
9:45 am | Compact Adenine Base Editor with Novel Microbial Components
Rafi Emmanuel
Senior Vice President, R&D
Emendo Biotherapeutics
Clarence Mills
Research Scientist
Horizon Discovery
